
|Videos|December 16, 2022
Cabazitaxel for the Treatment of mCRPC: Data From the PROSELICA and FIRSTANA Trials
Author(s)Neal Shore, MD, FACS
Neal Shore, MD, FACS, discusses data from the PROSELICA and FIRSTANA trials investigating cabazitaxel for the treatment of mCRPC, including a look at the post-hoc analyses of PROSELICA.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC
3
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
4
Interpreting PSMA PET Imaging in Prostate Cancer
5







